Martin R. Felsenthal is a Partner of HLM Venture Partners. Marty was previously a General Partner of Salix Ventures, where he focused on investments in health care services and health care information technology. Marty served on the boards of Vantage Oncology, US Renal Care, Ancillary Care Management, Vericare, AccentCare, Titan Health and Payerpath. At Salix, Marty was involved in helping management found a number of new businesses through platform acquisitions, including Vantage and Vericare. He also recruited more than 25 executives to the portfolio companies with whom he worked. He is currently a director of Aperio Technologies and Vericare Management and a board observer at Vantage Oncology. Marty also serves on the Board of the Northern California Chapter of the Crohn's and Colitis Foundation of America. He received a BA from Princeton University and an MBA from the Stanford University Graduate School of Business.